Adjuvant abemaciclib is currently recommended for patients with hormone receptor–positive/HER2-negative early breast cancer at high risk of recurrence, but many patients who meet the eligibility criteria do not receive it. Take this quiz to test your knowledge of the results of a recent real-world study, reported at the 42nd Annual Miami Breast Cancer Conference, that explored characteristics of patients who did not receive the recommended abemaciclib treatment.
